HUTCHMED (China) (HCM) Amortization (2014 - 2025)

HUTCHMED (China) (HCM) reported Amortization of $168.1 million for Q4 2025, down 30.32% quarter-over-quarter from $241.3 million in Q2 2021.

HUTCHMED (China) (HCM) Amortization (2014 - 2025) Analysis & Trends

HUTCHMED (China) (HCM) has 9 years of Amortization data on file, last reported at $168.1 million in Q4 2025.

Amortization for Q4 2025 came in at $168.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $531.0 million (changed N/A YoY), and the FY2025 annual result was -$39.2 million, up 69.79% from the prior year.
Amortization slipped to $168.1 million in Q4 2025 per HCM's latest filing, from $241.3 million in the prior quarter.
Over five years, Amortization peaked at $241.3 million in Q2 2021 and troughed at $110.5 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Amort. (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	-
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	-
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	-
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	31.86 Mn
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	-
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	-
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	-
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	HUTCHMED (China)	1.20 Bn	-273.24 Mn	-	168.13 Mn

Download Data